Serum hepcidin-25 level was measured by liquid chromatography-mass spectrometry. Mean follow-up period was 230 ± 139 days. One-year survival curve was drawn by Kaplan Meier
analysis and stratified into 2 groups by median value of serum hepcidin-25. Multivariable Cox proportional hazards regression analysis was used to calculate hazard ratio (HR) with selleckchem its 95% confidence interval (CI) for all-cause mortality, adjusted for age, gender, and estimated glomerular filtration rate. Results: Mean serum hepcidin-25 level was 55.3 ± 56.3 ng/ml (median, 39.7 ng/ml), and totally 48 patients died during the follow-up period (mortality, 53.9%). The one-year survival was significantly lower (approximately Δ17%) in the high serum hepcidin-25 group than in the low serum hepcidin-25 one. (Figure). Multivariable Cox analysis showed that the mortality HR for patients with high serum hepcidin-25 was 1.85 (95% CI, 1.05–3.34, p < 0.05). (Table). Conclusion: High serum hepcidin-25 level is a novel predictive marker for short term mortality in cancer
patients. VILLAZOR-ISIDRO ERIKA BIANCA1, PEGA-FLORES CHRISTINE JOY1, BROJAN JOHN CARLO1, SANTOS-ESTRELLA PAUL2, BAYACA JEANNE3 1Department of Medicine, St. Luke’s Medical Center, Quezon City; 2Section of Rheumatology, St. Luke’s Medical Center, Quezon City; 3Section of Nephrology, St. Luke’s Medical Center, buy AZD2014 Quezon City Introduction: Hyperuricemia in Chronic kidney disease has been associated with decline in renal function. Newer urate lowering drugs, such as Febuxostat, has shown favorable urate lowering effects among patients with gout. However, this has not been proven in asymptomatic hyperuricemia in CKD. Consequently, the correlation of urate lowering effect of Febuxostat with renal outcomes remains unclear. Methods: We examined the serum urate lowering effectiveness of Febuxostat 40 mg daily, among 83 Filipino CKD patients in Decitabine mw a
single, tertiary center from June 2011-September 2013. Serum uric acid level and serum creatinine were determined at baseline, and followed up at 6 and 12 months. Results: The study showed that there is a mean decrease in serum uric acid in patients after 6 months on Febuxostat from 9.27 mg/dl to 8.24 mg/dl (p value- < 0.00001), with a percent reduction of 13%. After 12 months, there is a further decrease in the serum uric acid of the patients to 7.8 mg/dl (p value- < 0.00001) with a 15% reduction. Serum uric acid percent change was correlated with serum creatinine change (%) at 6 months (r = −0.384, p-value = < 0.00001), this implies that an increase of percent change in sUA at 6 months is correlated with a decrease of percent change in creatinine at 6-months. At 12 months, similar correlation was demonstrated, however did not show significant results (r = −0.168, p-value = 0.129).